TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30842213

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX) - 60 min at 75% of age-predicted maximum heart rate
Number of subjects: 22

Group type: COMPARATOR
Intervention: No exercise (NE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aerobic exercise (EX) and No exercise (NE)
Number of subjects: 22
Study: 29166336

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (2 × 450 mg/d for 100 days)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Preemptive treatment (2 × 900 mg/d initiated at viral load of 400 CMV copies/mL or greater)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis
Number of subjects: 299

Group type: COMPARATOR
Intervention: Preemptive treatment
Number of subjects: 299
Study: 27362855

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 74
Study: 25199046

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Exposure group therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Stereotype confirmation concerns (SCC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Pre-treatment symptom severity, race, age, gender
Number of subjects: 74
Study: 23253305

Group type: EXPERIMENTAL
Intervention: Third wave cognitive therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Mentalization-based therapy
Number of subjects: 84
Study: 20010133

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham PRT
Number of subjects: 48

Group type: COMPARATOR
Intervention: High-intensity cycling
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined exercise (PRT + cycling)
Number of subjects: 48
Study: 17507365

Group type: EXPERIMENTAL
Intervention: Group I (remained in sinus rhythm)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Group II (recurrence of AF)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: APC/h and max HR
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination of both predictors (APC/h and max HR)
Number of subjects: 47
Study: 16327033

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein (CP) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No fluid (NF) group
Number of subjects: 0
Study: 12189364

Group type: COMPARATOR
Intervention: 30 mg ketorolac tromethamine (intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mg ketorolac tromethamine (intramuscular or submucosal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mg ketorolac tromethamine (at the surgical site)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10457293

Group type: EXPERIMENTAL
Intervention: Absorbent liners in cloth postural support nappies
Number of subjects: 23

Group type: COMPARATOR
Intervention: No absorbent liners in cloth postural support nappies
Number of subjects: 23
Study: 7475657

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 3371

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 3371
Study: 2197908

Group type: EXPERIMENTAL
Intervention: Fluconazole, 400 mg/d for 10 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amphotericin B plus flucytosine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 21
Study: 282084

Group type: EXPERIMENTAL
Intervention: Three distinct antihypertensive drugs, administered alone and combined two‐by‐two.
Number of subjects: 10294

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10294
Study: 31791209

Group type: EXPERIMENTAL
Intervention: Group D: voltage, 100 kVp, iodixanol, 270 mgI/mL
Number of subjects: 216

Group type: COMPARATOR
Intervention: Group A: voltage, 120 kVp; iohexol, 350 mgI/mL
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 216
Study: 31773310

Group type: EXPERIMENTAL
Intervention: Specific positioning of the EVD in the setting of intracerebral hemorrhage with intraventricular hemorrhage
Number of subjects: 0

Group type: COMPARATOR
Intervention: EVD management approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVDs
Number of subjects: 0
Study: 27846418

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 462
Study: 25973914

Group type: EXPERIMENTAL
Intervention: Bacillus clausii spores administered as lyophilized or liquid formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacillus clausii spores (liquid suspension)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacillus clausii spores (lyophilized form)
Number of subjects: 0
Study: 23332366

Group type: EXPERIMENTAL
Intervention: Nebivolol (NEB) 5 mg/d, titrated to 20 mg/d
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Nebivolol (NEB)
Number of subjects: 432
Study: 21277745

Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg once daily
Number of subjects: 301

Group type: COMPARATOR
Intervention: Ziprasidone 80 mg BID
Number of subjects: 301
Study: 19498438

Group type: EXPERIMENTAL
Intervention: Efonidipine (40 mg day(-1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amlodipine (5 mg day(-1))
Number of subjects: 60
Study: 16979844

Group type: EXPERIMENTAL
Intervention: Total dose 30 Gy (dose/fraction 1.5 Gy, 16 patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Total dose 25.5 Gy (dose/fraction 1.5 Gy, 62 patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Total dose 20 Gy (dose/fraction 2 Gy, 69 patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Total dose 26 Gy (dose/fraction 2 Gy, 29 patients)
Number of subjects: 191
Study: 15003662

Group type: EXPERIMENTAL
Intervention: Autoclaved‐killed, whole cell Leishmania amazonensis vaccine plus BCG adjuvant
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1506
Study: 17201277

Group type: EXPERIMENTAL
Intervention: mexicor
Number of subjects: 101
Study: 10224738

Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8550957

Group type: EXPERIMENTAL
Intervention: General practitioners' diagnosis of depression
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Symptoms described by GPs
Number of subjects: 682
Study: 1775603

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor HP 029 (doses not specified)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7029742

Group type: EXPERIMENTAL
Intervention: Diflunisal (Dolobid; Frosst‐MSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen (Naprosyn; Syntex)
Number of subjects: 0
Study: 31550817

Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study: 29351310

Group type: EXPERIMENTAL
Intervention: Small-group intervention of seven weekly sessions of 120 min with a booster session after six weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Small-group intervention
Number of subjects: 115
Study: 26710008

Group type: EXPERIMENTAL
Intervention: Subglandular breast augmentation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Submuscular breast augmentation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 23420196

Group type: EXPERIMENTAL
Intervention: Cognitive resource depletion condition
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study: 22159880

Group type: COMPARATOR
Intervention: Group B (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group BM (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group BC (bupivacaine 0.166% with epinephrine 1:600,000 plus clonidine 1.0 μg/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group BMC (bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg and clonidine 1.0 μg/kg)
Number of subjects: 80
Study: 19889003

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy with added pioglitazone (45 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study: 17337398

Group type: EXPERIMENTAL
Intervention: 200 mug/day selenium for 3 years
Number of subjects: 184

Group type: COMPARATOR
Intervention: Matching placebo for 3 years
Number of subjects: 184
Study: 15762971

Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (1 g intravenously before surgery)
Number of subjects: 548

Group type: COMPARATOR
Intervention: 1-day cefazolin (1 g intravenously before surgery and three more doses every 6 hr after surgery)
Number of subjects: 548
Study: 11879210

Group type: EXPERIMENTAL
Intervention: Propofol-ephedrine combination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 100
Study: 10220835

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients with pulmonary hypertension
Number of subjects: 84
Study: 7604787

Group type: EXPERIMENTAL
Intervention: Fluvastatin at 40 mg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gemfibrozil at 600 mg twice daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of fluvastatin and gemfibrozil
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 2196555

Group type: EXPERIMENTAL
Intervention: Codeine plus 1 g of paracetamol t.i.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Paracetamol t.i.d.
Number of subjects: 19
Study: 31888947

Group type: EXPERIMENTAL
Intervention: Postoperative outpatient review 3 weeks after hospital discharge, followed by commencement of cardiac rehabilitation (CR) from 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative outpatient review 6 weeks after hospital discharge, followed by CR commencement from 8 weeks
Number of subjects: 100
Study: 29954449

Group type: EXPERIMENTAL
Intervention: FFIT Follow Up Intervention group (FFIT-FU-I)
Number of subjects: 665

Group type: COMPARATOR
Intervention: FFIT Follow Up Comparison group (FFIT-FU-C)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: FFIT
Number of subjects: 665
Study: 27093610

Group type: EXPERIMENTAL
Intervention: GSK457 (40 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK457
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25142742

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (CV) to restore sinus rhythm (SR)
Number of subjects: 164
Study: 22142170

Group type: EXPERIMENTAL
Intervention: Positive Action program (intervention)
Number of subjects: 20
Study: 20919759

Group type: EXPERIMENTAL
Intervention: Adolescent substance involvement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adolescent-reported PTS symptoms
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Parent-reported adolescent PTS symptoms
Number of subjects: 80
Study: 17450046

Group type: EXPERIMENTAL
Intervention: Risperidone (1.08 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15050486

Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 231
Study: 12512791

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 20
Study: 9690573

Group type: EXPERIMENTAL
Intervention: Salmeterol powder (50 microg twice daily)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 8579657

Group type: EXPERIMENTAL
Intervention: Doppler study of the systolic to diastolic ratio of the umbilical artery
Number of subjects: 92
Study: 2569550

Group type: EXPERIMENTAL
Intervention: Routine fetal movement counting
Number of subjects: 68000

Group type: COMPARATOR
Intervention: Standard care (selective use of formal counting or informal noting of movements)
Number of subjects: 68000
Study: 560824

Group type: EXPERIMENTAL
Intervention: Starr-Edwards aortic valve replacement (SE-AVR)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Hancock aortic valve replacement (X-AVR)
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Starr-Edwards mitral valve replacement (SE-MVR)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Hancock mitral valve replacement (X-MVR)
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Starr-Edwards double-valve replacement (SE-AVR-MVR)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Hancock double-valve replacement (X-AVR-MVR)
Number of subjects: 1518
Study: 31778140

Group type: EXPERIMENTAL
Intervention: Ens-Grad machine learning method for designing complementarity determining regions of human Immunoglobulin G antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning approach
Number of subjects: 0
Study: 31503048

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium Nitroprusside
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerine
Number of subjects: 60
Study: 27631964

Group type: EXPERIMENTAL
Intervention: Integrated behavioral health home
Number of subjects: 447

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 447
Study: 26233289

Group type: EXPERIMENTAL
Intervention: N-palmitoylethanolamine (PEA) and transpolydatin: 400 mg + 40 mg (1 tablet a day for 10 days from the 24th day of cycle)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (1 tablet a day for 10 days from the 24th day of cycle)
Number of subjects: 220
Study: 23758736

Group type: EXPERIMENTAL
Intervention: BM-MSCs (2 million cells/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PlasmaLyte A)
Number of subjects: 20
Study: 20053471

Group type: EXPERIMENTAL
Intervention: FCE group
Number of subjects: 41

Group type: COMPARATOR
Intervention: RCE group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 18719439

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 and 0.6 ng/ml)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (up to 0.6 ng/ml)
Number of subjects: 37
Study: 15772567

Group type: EXPERIMENTAL
Intervention: Soy supplements (Novasoy, 60 mg total isoflavone equivalents/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11828224

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nutritional advice
Number of subjects: 15

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 15
Study: 10980842

Group type: EXPERIMENTAL
Intervention: Intravenous IIb/IIIa blockade
Number of subjects: 18000
Study: 8773291

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 51

Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 51
Study: 2344923

Group type: EXPERIMENTAL
Intervention: Formula with lactose as the sole carbohydrate (n = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Formula with 50% of the carbohydrate as glucose polymer (n = 8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Doubling the lactose intake
Number of subjects: 15
Study: 6253303

Group type: EXPERIMENTAL
Intervention: Hormones and hormones and thiazide
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Thiazide alone
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Fluoride
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Fluoride and D3
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: 1 alpha D3
Number of subjects: 315

Group type: COMPARATOR
Intervention: Combined placebo groups
Number of subjects: 315
Study: 30183583

Group type: EXPERIMENTAL
Intervention: TACE therapy
Number of subjects: 59
Study: 26956987

Group type: EXPERIMENTAL
Intervention: Exercise plus energy restriction (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Energy restriction alone (n = 30)
Number of subjects: 60
Study: 26301344

Group type: COMPARATOR
Intervention: Standard HF therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Overall HF therapy
Number of subjects: 70
Study: 23653910

Group type: COMPARATOR
Intervention: Paediatric fixed-dose combination granule for reconstitution (lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single entities of the referenced products (lamivudine, zidovudine, nevirapine)
Number of subjects: 24
Study: 19853922

Group type: EXPERIMENTAL
Intervention: Caregiver psychoeducation for Stage I patients
Number of subjects: 113
Study: 18086929

Group type: EXPERIMENTAL
Intervention: 162 mg aspirin
Number of subjects: 48422

Group type: COMPARATOR
Intervention: 325 mg aspirin
Number of subjects: 48422
Study: 15926000

Group type: EXPERIMENTAL
Intervention: Neoplastic meningitis-related encephalopathy cohort (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No neoplastic meningitis-related encephalopathy cohort (20 patients)
Number of subjects: 40
Study: 14679320

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy with methylene blue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 0
Study: 11008919

Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Type I strains of H. pylori
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Intermediate strains of H. pylori
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Type H strains of H. pylori
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: CagA protein antibodies
Number of subjects: 396
Study: 9504817

Group type: EXPERIMENTAL
Intervention: Protein expression profiles in ductal carcinoma specimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protein expression profiles in normal breast tissue
Number of subjects: 0
Study: 8341859

Group type: EXPERIMENTAL
Intervention: Fenoterol/Ipratropium Bromide (F/IB; 0.1 mg/0.04 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salbutamol (S; 0.2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study: 3786603

Group type: EXPERIMENTAL
Intervention: Intravenous GABA administration
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 7
Study: 30187306

Group type: EXPERIMENTAL
Intervention: Neurofeedback with Ritalin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neurofeedback without Ritalin
Number of subjects: 14
Study: 27116196

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) + usual care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 20
Study: 24766625

Group type: EXPERIMENTAL
Intervention: Fatiguing session with five sets of bilateral dynamic knee extensions to exhaustion using a load equal to the dominant limb MVC (1-min rest between sets)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control session (subjects sat)
Number of subjects: 18
Study: 23084163

Group type: EXPERIMENTAL
Intervention: Intervention athletes
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Intervention athletes (full-intensity implementation)
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 2006
Study: 19713950

Group type: COMPARATOR
Intervention: Metformin XR therapy (placebo-controlled trial)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Anthropometry and DXA measures
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: CT measures
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Regression model including waist circumference (WC) and BMI
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Regression model including TG:HDL ratio and IGFBP-1
Number of subjects: 92
Study: 18652113

Group type: EXPERIMENTAL
Intervention: Modified Simiao Tang (MST)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Allopurinol tablet
Number of subjects: 120
Study: 15975300

Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule (XST)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dahuang Zhechong pill (NFDA1)
Number of subjects: 64
Study: 14769157

Group type: EXPERIMENTAL
Intervention: Training program for health personnel including social, cultural, and economic aspects of tuberculosis, diagnosis and treatment, and establishment of self-help groups. Patients received a short-term treatment regimen with isoniazid, rifampin, pyrazinamide, and ethambutol for 25 weeks (105 doses).
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group received standard treatment without the educational intervention.
Number of subjects: 87
Study: 11760294

Group type: EXPERIMENTAL
Intervention: CON retention program intervention sessions with the Retention Coordinator
Number of subjects: 320

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 320
Study: 8866595

Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 microg)
Number of subjects: 30
Study: 1406078

Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon treatment 3 MU three times weekly for 36 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 33
Study: 3902912

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23